Skip to main content
. Author manuscript; available in PMC: 2017 Nov 10.
Published in final edited form as: Mayo Clin Proc. 2016 May 10:S0025-6196(16)00125-7. doi: 10.1016/j.mayocp.2016.02.012

FIGURE 2.

FIGURE 2

The strength of evidence between a surrogate-survival correlation for accelerated (A) and traditional (B) drug approvals based on surrogate end points. Level 1 studies were scored based on a modification to criteria proposed by the Institute for Quality and Efficiency in Health Care: low correlation (r≤0.7), medium correlation (r>0.7 to r<0.85), and high correlation (r≥0.85). No level 1 or 2 means that we could not identify a single association study in the literature. Where multiple level 1 studies exist, the median r was used for scoring.